193 related articles for article (PubMed ID: 34799660)
1. Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
Yin L; Zeng Y; Zeng R; Chen Y; Wang TL; Rodabaugh KJ; Yu F; Natarajan A; Karpf AR; Dong J
Oncogene; 2021 Dec; 40(50):6772-6785. PubMed ID: 34799660
[TBL] [Abstract][Full Text] [Related]
2. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
4. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
5. Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer.
Sun X; Diao X; Zhu X; Yin X; Cheng G
J Biochem; 2021 Sep; 169(6):747-756. PubMed ID: 33599261
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract][Full Text] [Related]
7. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
8. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
[TBL] [Abstract][Full Text] [Related]
9. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
10. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
[TBL] [Abstract][Full Text] [Related]
12. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
13. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
14. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
15. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis.
Ling YH; Tornos C; Perez-Soler R
J Biol Chem; 1998 Jul; 273(30):18984-91. PubMed ID: 9668078
[TBL] [Abstract][Full Text] [Related]
17. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
20. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]